Cambium Medical Technologies (“Cambium” or “the Company”) was founded in 2013 by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA). The Company is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular® a standardized, commercialized platelet derived biologic eye drop for dry eye (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular® is an investigational drug and is not yet approved for sale in or outside the United States. A Phase I/II FDA dry eye clinical study is underway at several U.S. sites to assess the safety and exploratory efficacy of Elate Ocular® among patients with a severe form of dry eye.
Since 2015 Cambium has commercialized through a strategic partner (Zheng Yang Biomedical Technology Co LTD, Taipei, Taiwan) the Company’s novel processed platelets (Aurarix®) in its partner’s line of UltraGRO™ stem cell growth supplements. Cambium remains committed to pursuing added applications of its Aurarix® novel platelets either directly or through strategic partners. For more information or to contact Cambium, please click on this link.
